Methylprednisolone is a synthetic glucocorticoid drug. It is sold in the USA and Canada under the brand names Medrol and Solu-Medrol.
Like most adrenocortical steroids, methylprednisolone is typically used for its anti-inflammatory effects. However, glucocorticoids have a wide range of effects, including changes to metabolism and immune responses. The list of medical conditions for which methlyprednisolone is prescribed is rather long, and is similar to other corticosteroids such as prednisolone. Common uses include arthritis therapy and short-term treatment of bronchial inflammation or acute bronchitis due to various respiratory diseases. It is used both in the treatment of acute periods and long-term management of autoimmune diseases, most notably Systemic lupus erythematosus.
Methylprednisolone has serious side effects if taken long-term, including weight gain, glaucoma, osteoporosis and psychosis, especially when overdosed. The most serious side effect occurs after the adrenal glands cease natural production of cortisone, which methylprednisolone will replace. Abrupt cessation of the drug after this occurs can result in a condition known as Addisonian crisis, which can be fatal. To prevent this, the drug is usually prescribed with a tapering dosage, including a pre-dosed "dose pack" detailing a specific number of pills to take at designated times over a six-day period.
Alternative treatments to many of the conditions currently indicated for methlyprednisolone are actively being researched. Additionally, new drugs such as budesonide are being created, which provide similar benefits but without the adrenal suppression problems.
Methlyprednisolone is also prescribed for spinal cord injuries(traumas). It has been proven that a dose of 30 mg/kg IV followed by IV drip at 5.4 mg / kg / hr for 23 hours improves sensory and motor recovery if given within 8 hours of the injury.
The prehospital administration of intravenous methylprednisolone lowers hospital admission rates for moderate to severe asthma
Oct 01, 2003; ABSTRACT Objective. To compare hospital admission rates for patients with moderate to severe asthma who receive intravenous...
Agency Reviews Patent Application Approval Request for "Taste-Masked Powder for Suspension Compositions of Methylprednisolone"
Aug 31, 2013; By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Lupin Limited has been issued patent application...
Recent findings in methylprednisolone therapy described by researchers from University of Virginia, Department of Neurology.
Aug 04, 2010; A report, 'Outcomes in treatment of infantile spasms with pulse methylprednisolone,' is newly published data in Journal of...